Hansoh Ris-Rez Hits OS Goal in China SCLC Trial

Key Takeaways

• ARTEMIS-008 met OS versus topotecan at a pre-specified interim analysis in relapsed/advanced SCLC after platinum therapy.
• Hansoh and GSK also reported consistent PFS benefit and no new safety signals.
• Companies frame the readout as the first Phase 3 OS success for a B7-H3–directed ADC.
• Hansoh will engage China's NMPA CDE on a BLA; GSK continues global development outside Greater China.

Ris-Rez ARTEMIS-008 at a glance

Field	Detail
Candidate	Risvutatug rezetecan (Ris-Rez / HS-20093)
Class	B7-H3–directed ADC (TOP1i payload)
Sponsor (China)	Hansoh Pharmaceutical Group
Global partner	GSK (ex–Greater China rights)
Trial	ARTEMIS-008 Phase 3 (China; NCT06498479)
Population	Advanced or relapsed SCLC after platinum
Primary endpoint	Overall survival vs topotecan — met
Next step	China BLA discussions with NMPA CDE

What did the companies announce?

Hansoh said Ris-Rez achieved statistically significant and clinically meaningful OS improvement over topotecan, with consistent secondary benefit including PFS. Full numerical tables were reserved for a future oncology congress. GSK separately confirmed the China Phase 3 win and reiterated its ex-China development plans.

Primary detail is in GSK's July 10 release on Hansoh's ARTEMIS-008 results. The study registry entry is on ClinicalTrials.gov for NCT06498479.

Why does relapsed SCLC need another option?

Small-cell lung cancer is highly aggressive; most patients relapse after first-line platinum regimens and face limited second-line choices and poor survival. B7-H3 is frequently expressed on SCLC tumours, making an ADC that delivers a topoisomerase inhibitor payload a mechanistically distinct approach versus chemotherapy alone.

FDA has previously granted Breakthrough Therapy designation for Ris-Rez in relapsed/refractory extensive-stage SCLC, reflecting U.S. interest alongside Hansoh's China path; designation context is summarized on FDA's Breakthrough Therapy page.

What should APAC observers watch next?

• Magnitude of OS and PFS deltas when congress data drop
• Timing and completeness of Hansoh's China BLA package
• How EMBOLD SCLC-301 reads out for GSK's global strategy
• Safety consistency versus prior Ris-Rez cohorts, especially hematologic toxicity typical of TOP1i ADCs

Until labeled, Ris-Rez remains investigational in China. Cross-trial comparisons with other relapsed-SCLC agents should wait for peer-reviewed absolute numbers rather than interim press language alone.

What remains uncertain?

Hazard ratios, median OS, subgroup consistency (including brain metastases), and detailed adverse-event rates were not in the July 10 wires. Regulatory acceptance of an interim OS claim still depends on NMPA review. Global rights outside Greater China sit with GSK, so China commercialization timelines and ex-China filings will not move in lockstep.

Related NovaPharma coverage

• NMPA Approves Iza-bren for ESCC in China
• NMPA Accepts Toripalimab Perioperative NSCLC sNDA
• Hansoh HS-10541 NMPA trial nod for KRAS G12C

Frequently Asked Questions

Primary Sources

1. GSK: Hansoh ARTEMIS-008 Phase 3 OS results — July 10, 2026
2. ClinicalTrials.gov: ARTEMIS-008 (NCT06498479)
3. FDA: Breakthrough Therapy designation overview